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Abstract
To identify loci affecting the electrocardiographic QT interval, a measure of cardiac repolarisation associated with risk of
ventricular arrhythmias and sudden cardiac death, we conducted a meta-analysis of three genome-wide association studies
(GWAS) including 3,558 subjects from the TwinsUK and BRIGHT cohorts in the UK and the DCCT/EDIC cohort from North
America. Five loci were significantly associated with QT interval at P,161026. To validate these findings we performed an in
silico comparison with data from two QT consortia: QTSCD (n = 15,842) and QTGEN (n = 13,685). Analysis confirmed the
association between common variants near NOS1AP (P = 1.4610283) and the phospholamban (PLN) gene (P = 1.9610229).
The most associated SNP near NOS1AP (rs12143842) explains 0.82% variance; the SNP near PLN (rs11153730) explains 0.74%
variance of QT interval duration. We found no evidence for interaction between these two SNPs (P = 0.99). PLN is a key
regulator of cardiac diastolic function and is involved in regulating intracellular calcium cycling, it has only recently been
identified as a susceptibility locus for QT interval. These data offer further mechanistic insights into genetic influence on the
QT interval which may predispose to life threatening arrhythmias and sudden cardiac death.
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Introduction
The QT interval on the electrocardiogram (ECG) represents the
period of ventricular depolarization and subsequent repolarisation.
Individuals with delayed cardiac repolarisation show a longer QT
interval and this predisposes them to the development of cardiac
arrhythmias. Patients with the rare Mendelian Long QT Syndrome
(LQTS) are at risk of sudden cardiac death [1]. Lengthening of the
heart-rate corrected QT interval within the normal range is
associated with increased coronary heart disease incidence and
mortality, as well as all-cause mortality [2,3]. QT prolongation is the
most common cause for withdrawal or restriction of drugs that have
already been marketed. Furthermore, many potentially valuable
drugs fail to be approved or are downgraded to second-line status
because they prolong QT and increase risk of serious life
threatening arrhythmias, especially torsade de pointes [4].
QT interval length is known to be influenced by various
parameters such as heart rate [5], age [6], sex [7], and medications
Phospholamban, NOS1AP, QT
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[8], and studies have suggested that QT interval at the population
level is a genetically influenced quantitative trait with up to 52%
heritability [9–11]. Until recently, research into genetic factors
influencing QT interval was limited to candidate genes known to
have a role in arrhythmogenesis on the basis of their involvement in
Mendelian Long or Short-QT Syndrome (LQTS or SQTS) [12–17].
However, an early genome-wide association (GWA) study [18]
identified a common genetic variant (rs10494366) in the nitric oxide
synthase 1 adaptor protein (NOS1AP) gene region, which has been
consistently associated with QT-interval variation across many
independent replication studies [19–24] The NOS1AP variant has
been estimated to explain up to 1.5% of QT variance [18], therefore
larger GWA studies of QT interval have the potential to detect
additional common genetic variants, likely of more modest effect size.
Recently, two consortia (QTGEN [25] and QTSCD [26]) reported
meta-analyses of GWAS of QT interval duration in population-based
cohorts, these papers describe a number of new loci [25,26].
We report a meta-analysis of three GWA studies totalling 3,558
individuals and test for association between QT interval duration and
approximately 2.4 million genotyped or imputed single nucleotide
polymorphisms (SNPs). Subsequently, we performed an in silico
comparison for our five most significant SNPs with QTGEN
(n=13,685) [25] and QTSCD (n=15,842) [26]. Our results confirm
the known association with the NOS1AP locus and QT interval
duration, more importantly it confirms the recently reported
association of variants near the PLN locus [25,26]. We found no
evidence of gene-gene interaction between NOS1AP and PLN.
Results and Discussion
Meta-analysis results from TwinsUK, BRIGHT and DCCT/
EDIC cohorts
The characteristics of the 3,558 individuals included in the
meta-analysis are shown in Table 1. Genome wide genotyping was
performed using a variety of platforms; therefore we imputed
genotypes using the HapMap CEU sample. A total of 2,399,142
genotyped or imputed SNPs met the inclusion criteria for our
study; we tested these for association with QT interval using an
additive model. We observed highly associated SNPs in five
chromosomal regions 1q23.3, 6q22.31, 13q13, 20p13 and 21q21.3
(Figure 1). Possible bias caused by population stratification was
checked by calculating the genomic inflation factor l of the meta-
analysis [27,28]. The l was 1.016 indicating our samples showed
little evidence for population stratification and therefore the results
of the meta-analysis were not adjusted (Figure 2). Table 2 shows
the results by cohort of the most significant SNP for each
associated region, Table S1 shows the results for all SNPs with
P,161026. One SNP (rs885170) near NBEA on chromosome 13
exceeded the genome-wide significance threshold, P = 561028
based on recent estimations of the genome-wide testing burden for
common sequence variation [29,30]. Four other SNPs had
P,161026. The first was rs12143842 (P= 2.161027), it is located
on chromosome 1, upstream of NOS1AP, a gene already identified
as prolonging QT interval [18]. The second SNP rs2832357
(P= 2.361027) is located on chromosome 21, near GRIK1, the
third rs11153730 (P= 6.461027) is located on chromosome 6 in
an intergenic region in a cluster of SNPs near three genes
SLC35F1, C6orf204 and PLN. The final locus, rs6038729
(P= 6.361027) is located on chromosome 20, near the BMP2
gene.
Results for known LQTS and SQTS candidate genes
There are 11 genes identified to date as being causative for
Mendelian single gene forms of LQTS and SQTS. Notably, both
of the recent GWAS meta-analyses [25,26] found that common
variants in a subset of these genes encoding ion channels, known to
cause the Mendelian LQTS, were the most strongly associated
with QT interval. We looked up the SNP with the lowest P-value
in each of these genes and up to 20 kb upstream and downstream.
Only one SNP in KCNE1 (LQT5; rs3787730 A.G; frequency
allele A: 31.7%; b<21.6 ms/allele A; P= 0.00045; Table S2) was
found to be significantly associated with QT interval, although not
genome-wide significant. This SNP was not in linkage disequilib-
rium with the polymorphisms D85N (rs1805128; r2 = 0.011;
Figure 1. Manhattan plot for QT interval based on GWAS meta-analysis of TwinsUK, BRIGHT, and DCCT/EDIC cohorts. SNPs are
ordered along the chromosomes on the x-axis. The 2log10 (P) results are plotted for 2,399,142 SNPs of the meta-analysis of TwinsUK, BRIGHT and
DCCT/EDIC cohorts for 3,558 individuals. The red dots indicate SNPs with P,1026.
doi:10.1371/journal.pone.0006138.g001
Table 1. Study characteristics of the TwinsUK, BRIGHT and
DCCT/EDIC cohorts.
TwinsUK BRIGHT DCCT/EDIC
N 1,048 1,392 1,118
Age, mean (SD) 51.8 (12.0) 56.7 (10.9) 46.0 (7.0)
Sex, n (%) male 12 (1.1) 502 (36.0) 568 (51.0)
QT interval, mean (SD) 400.9 (27.9) 414.5 (33.8) 387.6 (29.2)
aHypertensive, % 21.8 100 50.8
bDiabetic, % 3.1 0 100
aSystolic blood pressure .140 mmHg or diastolic blood pressure .90 mmHg
or taking anti-hypertensive drugs.
bType 1 or type 2 diabetes.
doi:10.1371/journal.pone.0006138.t001
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P=0.87) and rs727957 (r2 = 0.010; P= 0.090), which were
previously found to be associated with prolonged QT interval in
a general population [14,31]. None of the other genes showed
evidence for association with QT interval in our study.
Follow-up of the top 5 loci
To validate potential associations with QT interval we selected
the most associated SNP in each of the five regions from the
primary meta-analysis and conducted an in silico comparison with
data from the QTSCD and QTGEN consortia (Table 3). This
confirmed two of our five loci as being significantly associated with
QT interval in the replication at P = 561028; the strongest
evidence of association was with a SNP near NOS1AP, rs12143842
(P = 1.4610283). rs10494366 is the NOS1AP polymorphism most
commonly associated with QT interval in previous studies [19–
24], it reached a P-value of 0.035 in our data-set. This SNP is not
strongly correlated to rs12143842 in the HapMap CEU samples
(r2 = 0.102). The rs12143842 polymorphism explains 0.82%
variance of QT interval in our meta-analysis.
The second significantly associated locus was at chromosome
6q22.31, near the SLC35F1/C6orf204/PLN loci (rs11153730;
P = 1.9610229, Table 3; Figure 3). This SNP is intergenic in a
region with only a few genes. Little is known about SLC35F1 and
C6orf204, however the most plausible candidate gene is phospho-
lamban (PLN), an inhibitor of the Ca2+-ATPase isoform 2a
(SERCA2a), a Ca2+ transporting intracellular pump located in the
sarcoplasmic reticulum (SR) of cardiac muscle cells. The most
associated SNP rs11153730 is strongly correlated with two intronic
SNPs (rs3752581 and rs13192336) in PLN (r2 of 0.7 in HapMap
CEU samples). Both SNPs are associated with QT interval
P= 7.361024; both imputed.
The frequency of the C allele of rs11153730 near PLN was
consistent across studies (48.4% in TwinsUK; 48.1% in BRIGHT;
49.0% in DCCT/EDIC). Each C allele prolongs the standardized
QT interval by 0.122 units (corresponding to ,2.5 ms) and
explains 0.74% variance of QT interval duration (Table 2). The
effect size from combining all studies was lower, 0.09 with 0.40%
explained variance (Table 3). This decrease in effect size is not
unexpected and may be attributed to the ‘‘winner’s curse’’
phenomenon [32].
The effects of the NOS1AP and PLN loci did not show significant
heterogeneity between the three studies as tested by the Q test
(P.0.05, Table S1) [33], in total the two most significant loci in
our initial meta-analysis explain c. 1.6% of the variance in QT
interval duration. We also investigated whether there was any
evidence for a gene-gene interaction between the two most
significantly associated SNPs in the NOS1AP (rs12143842) and
PLN (rs11153730) genes. Analysis revealed no evidence to suggest
this (P = 0.99).
Phospholamban and QT interval length
Phospholamban (in its unphosphorylated state) is an inhibitor of
the Ca2+-ATPase isoform 2a (SERCA2a), a Ca2+ transporting
intracellular pump located in the SR of cardiac muscle cells. The
SR controls contraction and relaxation by regulating intracellular
calcium levels. Phosphorylation of PLN reduces inhibition of
SERCA2a, leading to activation of the Ca2+ pump, enhanced
muscle relaxation rates and decreased Ca2+ levels, thereby
contributing to the contractile response elicited by beta-agonists
[34,35].
PLN knock-out mice exhibit increased rates of basal myocardial
contraction as well as increased rates of basal myocardial
relaxation [34,35]. However, the enhanced contractility observed
with PLN knockout mice is in contrast to humans lacking PLN who
develop a lethal cardiomyopathy. Indeed, several rare (non-
HapMap) mutations in the human PLN gene have been associated
with either dilated [36] or hypertrophic cardiomyopathy [37],
presumably caused by PLN mediated over-inhibition [38,39] or
chronic activation of SERCA2a [37] respectively. Interestingly,
some of the individuals in the study of Haghighi et al. [40] who
were heterozygous for an Arg14Del mutation presented with
ventricular extra systolic beats and ventricular tachycardia.
It has previously been shown that prolongation of cardiac
repolarization elevates intracellular Ca2+, potentially increasing
the risk of arrhythmias [41]. Del Monte et al. [42] reported that
over-expression of SERCA2a in rats reduced ventricular arrhyth-
mias in an ischemia/reperfusion model. Recent evidence showed
that intracellular Ca2+ may also influence K+ currents and, thus
duration of the action potential [43]. Suppression of SERCA2a by
PLN may reduce SR Ca2+ content and lead to QT interval
shortening through calmodulin kinase II-dependent alterations in
K+ currents [44], whereas SERCA2a over-expression may result
in an increased Ca2+ content and QT interval prolongation as
shown in mice without underlying cardiac disease [43].
In addition to PLN, neuronal nitric oxide synthase (NOS1) is
also involved in regulating intracellular calcium cycling [45].
NOS1AP is a regulator of NOS1. Furthermore, a recent study of
transgenic mice with cardiomyocyte-specific NOS1 over-expression
suggested that the greater intracellular Ca2+ transients, and SR
Ca2+ load in these mice following treatment to induce cardiac
hypertrophy could be explained, at least in part, by modulation of
PLN phosphorylation status [46]. In fact, nNOS-derived NO has
Figure 2. Quantile-quantile plots of association results of the
meta-analysis from TwinsUK, BRIGHT and DCCT/EDIC cohorts.
Based on 2,399,142 SNPs in 3,558 individuals from the combined
cohorts. The 2log10(P) plot of association test for QT interval is shown
for all SNPs (black diamonds) and for all SNPs except those located
within 1 Mb of the most significant SNPs of our five associated regions
(dark grey) [26]. Genomic Control l was 1.016 [25]. The lower horizontal
line denotes the 95% percentile of the results of all SNPs, values lower
than this threshold were used for calculating the l. The upper line
indicates the point from where P-values of the complete dataset
deviate from the expected line.
doi:10.1371/journal.pone.0006138.g002
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Table 3. Results of the five most significant loci from GWAS meta-analysis of TwinsUK, BRIGHT and DCCT/EDIC cohorts and in silico
comparison with the QTGEN and QTSCD consortia data.
SNP Chr Positiona
Flanking genes (distance
to SNP in kb) Coded Allele
Meta-analysis of TwinsUK,
BRIGHT and DCCT/EDIC QTSCD QTGEN META
rs12143842 1 160,300,514 OLFML2B; NOS1AP Freq T (%) 26 24 26 25
(240.2; 5.7) Beta 0.15 0.16 0.21 0.18
P-value 2.1 1027 1.6 10235 8.1 10246 1.4 10283
rs11153730 6 118,774,215 SLC35F1;C6orf204;PLN Freq C (%) 48 50 50 50
(228.7; intronic; 202.0) Beta 0.12 0.091 0.08 0.09
P-value 6.4 1027 5.2 10216 5.3 10210 1.9 10229
rs885170 13 34,095,789 RFC3; NBEA Freq G (%) 19 20 20 20
(2657.1; 318.7) Beta 0.18 20.011 20.0051 0.01
P-value 1.8 1028 0.44 0.76 0.28
rs6038729 20 7,085,757 BMP2; FUSIP1P2 Freq C (%) 31 32 31 32
(2367.8; 675.3) Beta 0.13 0.020 20.0042 0.023
P-value 6.3 1027 0.085 0.76 0.0071
rs2832357 21 29,785,765 BACH1; GRIK1 Freq G (%) 3 3 3 3
(2129.7; 45.4) Beta 0.40 0.0075 0.022 0.053
P-value 2.3 1027 0.82 0.58 0.031
Freq: allele frequency.
aNCBI Genome build 36.3.
doi:10.1371/journal.pone.0006138.t003
Table 2. Results of the most significant SNP from the five regions associated with QT interval in GWAS meta-analysis of TwinsUK,
BRIGHT and DCCT/EDIC cohorts.
SNP ID Cohort
Coded Allele
Frequency (%) HWE (P) Genotyped Beta (SE) R2 (%)a P-value
rs12143842, chr 1 TwinsUK 24.4 0.11 No 0.22 (0.053) 1.76 3.261025
coded allele: T BRIGHT 26.6 0.89 No 0.15 (0.046) 0.83 0.0015
non-coded allele: C DCCT/EDIC 25.3 0.68 Yes 0.085 (0.049) 0.27 0.082
Meta 25.5 N/A N/A 0.15 (0.028) 0.82 2.161027
rs11153730, chr 6 TwinsUK 48.4 0.024 No 0.21 (0.145) 2.19 3.661026
coded allele: C BRIGHT 48.1 0.45 No 0.096 (0.04) 0.46 0.017
non-coded allele: T DCCT/EDIC 49 0.75 No 0.075 (0.042) 0.28 0.076
Meta 48.5 N/A N/A 0.12 (0.024) 0.74 6.461027
rs885170, chr13 TwinsUK 18.7 0.28 No 0.17 (0.058) 0.84 0.0045
coded allele: G BRIGHT 19.7 0.41 No 0.22 (0.051) 1.58 1.261025
non-coded allele: A DCCT/EDIC 17.6 0.76 No 0.14 (0.057) 0.55 0.016
Meta 18.8 N/A N/A 0.18 (0.032) 0.99 1.861028
rs6038729, chr20 TwinsUK 32.3 0.98 Yes 0.064 (0.046) 0.18 0.16
coded allele: C BRIGHT 30.1 0.14 No 0.21 (0.044) 1.87 2.161026
non-coded allele: A DCCT/EDIC 32.3 0.78 Yes 0.11 (0.046) 0.54 0.015
Meta 31.4 N/A N/A 0.13 (0.026) 0.73 6.361027
rs2832357, chr 21 TwinsUK 2.7 0.77 Yes 0.27 (0.16) 0.37 0.088
coded allele: G BRIGHT 2.8 0.2 No 0.49 (0.12) 1.29 5.361025
non-coded allele: A DCCT/EDIC 2.6 0.21 Yes 0.38 (0.13) 0.71 0.0031
Meta 2.7 N/A N/A 0.40 (0.076) 0.82 2.361027
HWE: Hardy-Weinberg equilibrium test; SE: standard error; N/A: not applicable.
aPercentage of explained variance.
doi:10.1371/journal.pone.0006138.t002
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been shown to regulate myocardial relaxation and intracellular
Ca2+ decay by promoting PKA-mediated PLN phosphorylation
[47] and in nNOS2/2 myocytes, decreased PLN phosphorylation
has been shown to decrease the rate of SR Ca2+ reuptake and
impair relaxation by inhibiting SERCA2a activity. Whether
abovementioned mechanisms are similar in humans awaits
confirmation in future studies.
In addition to interaction with the SERCA genes (ATPT2A1
and ATP2A2) and NOS1, it has also been suggested that PLN
interacts at the protein level with a number of molecules involved
in ATP-dependent transport of Ca2+ (Figure S1). Furthermore,
PLN is highly expressed in muscle and heart tissue and is co-
expressed with muscle, or heart specific genes (Figures S2 and S3).
Together with the data described above these observations suggest
that PLN is most likely to influence QT interval through
regulation of myocellular calcium cycling.
The current findings indicate that maintaining normal homeo-
static calcium cycling is crucial as when imbalanced it can lead to
human heart failure. However, PLNmay also play a role in cardiac
repolarization, which again if disturbed leads to serious arrhyth-
mias. Earlier studies have suggested screening for PLN mutations
in individuals with dilated cardiomyopathy [48,49]. In view of the
fact that both super-inhibition, as well as, over-expression of
SERCA2a by PLN may lead to cardiomyopathy and heart failure,
it maybe that any therapies directed at PLN will be challenging to
develop without disturbing the fine balance between SERCA2a
and PLN.
Apart from the discovery of variants in genes causing LQTS
and SQTS [13,14,25,26,50] and NOS1AP [18–26], very few
variants have thus far been consistently associated with QT
interval duration in the general population. Our study with 3,558
individuals illustrates the potential of GWAS to identify novel
variants playing a role in determining QT interval duration. Our
results highlight the consistent role of NOS1AP genetic variants in
modulating QT interval and confirm the recently identified PLN
locus. Despite only two loci reaching genome-wide significance
overall, and their effects, although positive are modest (,1% of
variance), these results must be considered in the context of our
sample size. Meta-analyses of larger datasets will no doubt identify
additional SNPs with smaller effects or with rarer allele frequencies
associated with QT interval.
In summary, our study is amongst the first to report common
variants near PLN associated with QT interval. Functional
relevance of PLN to QT interval duration is supported, it has a
well documented role in myocellular calcium cycling, our results
suggest that further molecular and functional analyses of this gene
is warranted to pursue its role in regulating QT interval duration.
Furthermore, genetic variation in the NOS1AP gene has also been
Figure 3. Regional association plot for the SLC35F1/C6orf204/PLN locus on chromosome 6. Shown is the region extending to 500 kb either
side of the most associated SNP rs11153730. The SNPs are illustrated on 2log10(P) scale as a function of chromosomal position (NCBI build36.3). The
sentinel SNP is illustrated in blue. Surrounding SNPs are coloured according to their r2 with rs11153730 (red indicates an r2.0.8, orange an r2 of 0.5–
0.8, yellow an r2 of 0.2–0.5 and grey an r2 of less than 0.2).
doi:10.1371/journal.pone.0006138.g003
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associated with risk of mortality in patients using both cardiac and
non-cardiac drugs [51,52]. Therefore the observed association
between PLN and QT interval may also have implications for
cardiac and non-cardiac drug development, as QT prolongation is
a very common reason for cessation of development or withdrawal
of drugs. Further investigation into the potential interaction
between PLN variants and drug-induced QT prolongation would
also be of great interest.
Materials and Methods
Ethics Statement
All subjects involved in the study gave fully informed written
consent for the collection of samples and subsequent analysis. The
TwinsUK study received written ethical approval for this study
from the National Research Ethics Service (St. Thomas’ Research
Ethics Committee Ref. EC04/015). The BRIGHT study received
written ethical approval from The London Multicentre Research
Ethics Committee. The DCCT/EDIC study received written
ethical approval from The Hospital for Sick Children Research
Ethics Board.
Study subjects and SNP genotyping
The TwinsUK Study. Samples from the TwinsUK cohort
were genotyped with the Infinium assay (Illumina, San Diego,
USA) across three fully compatible SNP arrays, the Hap300 Duo,
Hap300, and Hap550 [53]. SNP calling was performed using the
Illuminus software [54]. SNPs were excluded if they violated
Hardy–Weinberg equilibrium (HWE) (p,1.061024); had
genotype call rates ,90%; or had a minor allele frequency
(MAF) of less than 0.01. Individuals were excluded if the sample
call rate was less than 95%, autosomal heterozygosity was not
between 33 and 37%, genotype concordance was over 97% with
another sample and the sample was of lesser call rate, non-
caucasian ancestry either self-identified or identified by cluster
analysis in STRUCTURE [55], or unexplained relatedness
(estimated proportion of allele shared identical by descent .0.05
[56]) to .120 other samples. This resulted in GWAS data being
available on 305,912 SNPs for 2,256 individuals from 595
dizygotic (DZ) twin pairs and 1066 singletons (among them
twins from monozygotic (MZ) twin pairs) from the TwinsUK
cohort. This cohort was previously shown to be representative of
the general (singleton) UK population [57]. ECG data were
available on 1,104 of these individuals. Eight hundred and sixty
had automated measurements of the QT interval by the Cardiofax
ECG-9020K (Nihon Kohden UK Ltd., Middlesex, UK) and 244
were scored manually using a high-resolution digitizing board
(GTCO CalComp Peripherals, USA).
Fifty six individuals were removed from the data set because of
atrial fibrillation, QRS duration .120 ms or presence of a heart
condition (i.e. ischemic heart disease, stroke or bypass surgery). None
of the genotyped twins had a pacemaker or used anti-arrhythmic
drugs. The dataset for analyses consequently included 1,048
individuals, of which 588 were DZ twins (i.e. 294 pairs) and 460
singletons. These singletons included 235 MZ twins of which the
mean QT interval of both twins was used to optimise information.
The BRIGHT study. Two thousand unrelated white European
hypertensive individuals from the BRIGHT study (www.brightstudy.
ac.uk) were genotyped with the GeneChip Human Mapping 500K
Array Set (Affymetrix). Only individuals and SNPs passing WTCCC
thresholds for quality control [58] were included in the analysis.
Briefly, individuals were excluded if they had .3% missing data or
evidence of non-Caucasian ancestry under Eigenstrat analysis [59].
SNPs were excluded if they showed deviation from HWE
(p,561027), high levels of missing data (capture rate ,95%) or
lowMAF (,1%). Twelve-lead ECG recordings (Siemens-Sicard 440;
http://www.brightstudy.ac.uk/info/sop04.html), which produces an
automated measurement of the QT interval, were available for all
subjects. All data were transferred from each recruitment centre by
electronic modem to electrophysiologists from the West of Scotland
Primary Prevention Study (Professor Peter MacFarlane) for central
reporting. Thirteen hundred and ninety two individuals remained in
the analysis after exclusion of those having ischemic disease, stroke, or
bypass, atrial fibrillation, or QRS duration .120 ms and having full
covariate information.
The DCCT/EDIC Study. The Diabetes Control and
Complicatons Trial (DCCT)/Epidemiology of Diabetes
Interventions and Complications (EDIC) study was a clinical
trial and follow-up of subjects with type 1 diabetes. Fourteen
hundred forty one patients with type 1 diabetes were recruited for
the DCCT [60] and followed-up in EDIC [61]. Genome-wide
genotyping in subjects from the DCCT/EDIC was performed
using the Illumina 1 M beadchip assay (Illumina, San Diego,
USA) of which 841,342 SNPs with a MAF.1% were subsequently
analyzed statistically. Autosomal SNPs showing significant
association with gender (p,1028) or deviating from HWE
(p,1028) were excluded from the analysis. To reduce the
possibility of population stratification, we limited the analysis to
individuals who self-identified as white, and excluded individuals
who were determined to be admixed between Caucasian and
other ethnic groups through population genetic approaches, using
Eigenstrat [59] seeding with genotype data from the three major
populations genotyped in HapMap Phase II [62].
Twelve-lead resting ECGs were obtained by a certified
technician or research nurse at 29 clinics, measured digitally and
read according to the revised Minnesota Code at the Central ECG
Reading Unit (University of Minnesota, under the direction of Dr.
Richard S. Crow) [63]. In brief, at least 1 full min of ECG tracing
was obtained consisting of 5 s of each of the leads (I, II, III,
aVR,aVL, aVF, and V1–V6). Additionally, individuals having
ischemic disease, stroke, or bypass, atrial fibrillation, or QRS
duration .120 ms were excluded, therefore in total 323
individuals were excluded from the analysis.
Imputation
As all three cohorts used different platforms for genome wide
genotyping, non-genotyped autosomal SNPs were imputed. For
TwinsUK and BRIGHT individuals imputation was performed
using Phase II CEU HapMap data (release 22, build 36) as the
reference database using IMPUTE version 0.3.2 [64]. For
DCCT/EDIC individuals imputation was performed using Phase
II CEU HapMap data (release 22, build 36) using MACH v 1.0.16
[62,65].
Statistical Analyses
Using regression analysis, we adjusted QT interval for RR
interval, age, sex, height, body mass index, hypertension, and QT
interval shortening or prolonging drugs (if available) within each
cohort. For the TwinsUK sample, an extra covariate for the
method of measurement (automatically vs. manually scored) of the
QT interval was incorporated. Standardized QT interval residuals
were used for further analyses. For the TwinsUK and BRIGHT
cohorts, association between standardized corrected QT interval
data and autosomal SNPs was tested with an F-test in SNPTEST
version 1.1.4 using an additive model and the proper option to
account for the uncertainty of the genotypes that were imputed
[64]. As the TwinsUK cohort data consisted partly of dizygotic
twins, the variances of the regression coefficients were corrected
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for the sibship relations using the Huber-White method for robust
variance estimation in R [66,67]. In the DCCT/EDIC cohort,
SNPs were tested for association with corrected QT interval using
an additive model in MACH2QTL version 1.04 [62,65]. Genomic
control was performed to check for population stratification [27].
A meta-analysis was conducted in R using the inverse variance-
weighted fixed effects method on the beta estimates relative to a
consistent reference allele to combine the results of TwinsUK,
BRIGHT, and DCCT/EDIC cohorts (own software). Only SNPs
with MAF.1%, P.1026 for the HWE test calculated using the
genotypes inferred after imputation by maximum likelihood
expectation and an imputation quality score reflecting the
observed by expected variance ratio .0.5 for TwinsUK and
BRIGHT (IMPUTE proper_info) and .0.3 for DCCT/EDIC
(MACH r2) were included in the analysis. Heterogeneity of
observed effects was tested by the Q test [33].
QTSCD and QTGEN ‘in silico’ cohorts: description,
genotyping and analysis
The QTSCD consortium conducted a meta-analysis of results
of GWAS on QT interval from the ARIC, SardiNIA, KORA,
GenNOVA and HNR cohorts comprising in total 15,842
individuals (in press [26]). The QTGEN consortium combined
the results of GWAS on QT interval from the Framingham Heart
Study, the Rotterdam Study, and the Cardiovascular Health study
in a meta-analysis including in total 13,685 individuals (in press
[25]). Both studies imputed genotype data in order to facilitate the
comparison of genotyping results across different platforms.
Further details of materials and methods of both consortia can
be found elsewhere (in press [25,26]).
We performed a meta-analysis combining our results with those
of the QTSCD and the QTGEN consortia for our five most
statistically significant independent SNPs using methods as
described above.
Supporting Information
Figure S1 PLN protein-protein interaction network. This
protein-protein interaction network was generated by the
STRING program (http://string.embl.de) after querying the
PLN gene using a high confidence score (0.700). Data supporting
the interactions illustrated were derived from experimental studies
(purple lines), databases (blue lines) and text mining (green lines).
The genes that are involved in the calcium signaling pathway are
indicated in red, the nodes with purple stars indicate the genes that
are associated with cardiovascular diseases as based on functional
annotation by DAVID (http://david.abcc.ncifcrf.gov). Only for
large nodes are 3D protein structures available in STRING. The
colour of the nodes does not encode any information.
Found at: doi:10.1371/journal.pone.0006138.s001 (0.22 MB
DOC)
Figure S2 PLN co-expression network. This network is retrieved
from the gene co-expression database COXPRESdb (http://
coxpresdb.hgc.jp) using the PLN Entrez ID (5350) as the query.
The co-expression network is drawn based on rank of correlation
from 123 Human microarray experiments released by the NCBI
GEO database. The bold grey lines indicate average ranks from 1
to 4. The normal light gray lines indicate average ranks from 5 to
29. The orange lines indicate conserved co-expression based on
evidence from the NCBI HomoloGene database and COX-
PRESdb. The gene names in red indicate muscle or heart specific
expression and nodes with purple stars refer to genes that are
associated with cardiovascular diseases as based on functional
annotation by DAVID (http://david.abcc.ncifcrf.gov). For large
nodes 3D protein structures are available in STRING. The colour
of the nodes does not encode any information.
Found at: doi:10.1371/journal.pone.0006138.s002 (0.13 MB
DOC)
Figure S3 Tissue-specific expression of PLN. (source: co-
expressed gene database COXPRESdb: http://coxpresdb.hgc.jp.
Calculation is based on the 123 human microarray experiments
released by NCBI GEO version 7.)
Found at: doi:10.1371/journal.pone.0006138.s003 (0.04 MB
DOC)
Table S1 All SNPs with p,10–6 for the additive model from the
meta-analysis of the TwinsUK, BRIGHT and DCCT/EDIC
cohorts.
Found at: doi:10.1371/journal.pone.0006138.s004 (0.05 MB
XLS)
Table S2 Most significant SNPs from the meta-analysis of
TwinsUK, BRIGHT and DCCT/EDIC cohorts within an area
20 kb upstream and downstream of the 11 known candidate genes
for LQTS and SQTS.
Found at: doi:10.1371/journal.pone.0006138.s005 (0.04 MB
DOC)
Appendix S1 Consortium members and affiliations
Found at: doi:10.1371/journal.pone.0006138.s006 (0.06 MB
DOC)
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